This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Celldex Therapeutics Inc (CLDX)

NASDAQ: Health Care

Company Cash Flow
Dec 2013 Dec 2012 Dec 2011 Dec 2010
Cash Flow From Operating Activities
Net Income (Loss) -81.55M -59.12M -44.80M -2.53M
Operating Gains/Losses -21.00K -80.00K -53.00K -42.00K
Extraordinary Gains / Losses 0.00 0.00 0.00 0.00
(Increase) Decrease In Receivables -445.00K 126.00K 154.00K 220.00K
(Increase) Decrease in Inventories 0.00 0.00 0.00 0.00
(Increase) Decrease In Other Current Assets 0.00 0.00 0.00 0.00
(Decrease) Increase In Payables 7.24M 3.76M 2.08M -1.19M
(Decrease) Increase In Other Current Liabilities 0.00 0.00 0.00 0.00
(Increase) Decrease In Other Working Capital 1.59M 499.00K -104.00K -35.66M
Other Non-Cash Items 4.64M 2.52M 2.65M 3.53M
Net Cash From Continuing Operations -67.67M -49.78M -35.66M -30.37M
Net Cash From Discontinued Operations 0.00 0.00 0.00 0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities -67.67M -49.78M -35.66M -30.37M
Sale of Property, Plant & Equipment 0.00 0.00 0.00 0.00
Cash Used for Investing Activities
Sale of Short-Term Investments 38.89M 52.36M 51.00M 42.38M
Purchases of Property, Plant & Equipment -4.22M -303.00K -509.00K -2.10M
Acquisitions 0.00 0.00 0.00 0.00
Purchases of Short-Term Investments -112.12M -69.26M -52.72M -56.52M
Other Cash from Investing Activities 21.00K 218.00K 0.00 0.00
Cash Provided by Financing Activities
Net Cash From Investing Activities -77.42M -16.98M -2.16M -16.16M
Issuance of Debt 0.00 0.00 5.00M 10.00M
Cash Used for Financing Activities
Issuance of Capital Stock 0.00 83.78M 36.02M 1.01M
Repayment of Long-Term Debt 0.00 0.00 -12.50M -197.00K
Repurchase of Capital Stock 0.00 0.00 0.00 0.00
Payment of Cash Dividends 0.00 0.00 0.00 0.00
Other Financing Charges, Net 289.60M -4.03M -86.00K 0.00
Net Cash From Financing Activities 289.60M 79.76M 28.43M 10.82M
Effect of Exchange Rate Changes -3.00K 2.00K -9.00K 2.00K
Net Change in Cash & Cash Equivalents 144.50M 13.00M -9.39M -35.72M
CLDX News

CLDX Celldex Therapeutics Inc

Analysts Ratings for CLDX

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 7 7 5 6
Moderate Buy 0 0 0 0
Hold 0 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
GET CLDX ANALYST REPORT

Brokerage Partners

CLDX Chatter

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs